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Abstract 
In a developing country like Bangladesh the Pharmaceutical industry as a whole play a vital role in the 
progress of economicdevelopment. But the net profit of this industry has decreased for the last few years. In 
this paper we have tried to analyze the financial performance of Selected Pharmaceutical Companies 
in Bangladesh which is measured in terms of Ratio (Profitability, Liquidity, Solvency and Activity ratio) 
Analysis and in terms of Testing Financial Soundness by using Multivariate Discriminate Analysis (MDA) as 
developed by Prof. Altman. For the source of data mainly relied on Annual Reports and official records. It 
was observed from the study of the financial statement of the Pharmaceutical industry that the profit earning 
capacity, liquidity position, financial position and the performance of the most of the Pharmaceuticals are not 
in sound position and it was also observed that the most of the Pharmaceuticals has a lower level position of 
bankruptcy. The reasons behind this position of the industry are inefficiency of financial management, 
absence of realistic goals, strict government regulation and increased cost of raw-materials, labor and 
overhead. The financial performance should be improved immediately. Therefore, the appropriate authority 
should take measures for the removal of the above problems. 
Keywords: Financial Performance, Ratio Analysis, Pharmaceuticals Industry, Multivariate Discriminate 
Analysis (MDA). 
  
1. Introduction 
Publicly traded companies are the economic pulse of a nation. Their birth, prosperity and demise generally 
reflect the financial condition of the country. A fairly reliable index of an economy in its process of growth 
and development is the rate of growth and decline of publicly traded companies. With the rapid growth of 
trade, commerce and industries, the numbers of publicly traded companies are considerably increasing 
in Bangladesh. These companies play a vital role on the economy of the country. Pharmaceutical is an 
important adjunct of industrialization in the country. Analyzing the Industrial Life Cycle, it has been found 
that all of the listed companies have just reached the middle stage. No company could reach the maturity 
stage. In a word, the Pharmaceutical industry of the country is just improving.  It is well known that this 
industry is one of the key to earning foreign currency and it plays an important role on the export of the 
country. On the other hand, most of the internal demand for drugs is fulfilled by the domestic Pharmaceutical 
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industry of the country. But Pharmaceutical industry of Bangladesh depends on foreign country for 
raw-material and technology. Now the time to make the Pharmaceutical firms self sufficient for the 
betterment of the country. At this time, performance of manufacturing enterprise, like Pharmaceutical, needs 
to be measured and analyzed. But evaluation of performance is not a regular practice in the country. Against 
this backdrop this study is an attempt to evaluate performance of some selected Pharmaceuticals for the 
period under study. To evaluate the financial performance of the Pharmaceuticals, the technique of financial 
analysis has been applied. Among the various tools of financial analysis the most important one is the ratio 
analysis. It is very helpful to gain valuable insight into the financial position, operation and financial 
problems of a particulars enterprise. Moreover, Multivariate Discriminate Analysis (MDA) is used which is 
developed by Professor Altman to examine the overall financial soundness. Some statistical tools like mean, 
standard deviation, and T-test are used to evaluate the performance. 
  
2. Objectives of the study 
The study is designed to achieve the following objectives: 
(i)     To assess the financial performance of the selected Pharmaceuticals firms. 
(ii)   To test the financial strengths and weaknesses of selected Pharmaceuticals firms. 
(iii) To pinpoint the causes of poor financial performance and suggest some measures to overcome the 
problems. 
  
3. Hypothesis 
The research is based on following hypothesis. 
H0: There is no significant difference between the industry mean and the individual firm’s ratio. 
H1: There is significant difference between the industry mean and the individual firm’s ratio. 
  
  
  
4. Methodology of the study 
Data has been taken from a sample of 9 Pharmaceuticals in Bangladesh. For the study only A and B category 
Pharmaceuticals are considered. “A” category Pharmaceutical includes those Pharmaceuticals that hold 
annual general meeting (AGM) and declare minimum 10% dividend regularly. The trading time of “A” 
category Pharmaceutical’s share is T+3. “B” category Pharmaceutical includes those Pharmaceuticals that 
hold annual general meeting (AGM) regularly but declare dividend at a rate below 10% on a regular basis. 
The trading time of “B” category Pharmaceutical’s share is also T+3. “Z” category Pharmaceutical includes 
those Pharmaceuticals that neither hold annual general meeting (AGM) nor declare dividend on a regular 
basis. The trading time of “Z” category Pharmaceutical’s share is T+7. Moreover, the size of the 
Pharmaceuticals, availability of information, and year of establishment are also considered for selecting the 
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Pharmaceuticals. The study covers a three year period from 2005-06 to 2007-08. This study is based on 
secondary data. Secondary data are the annual reports of the selected Pharmaceuticals firms and various 
studies made available through library work. The collected data have been tabulated, analyzed and 
interpreted with the help of different financial ratios, Multivariate Discriminate Analysis (MDA) and 
statistical tools like mean, S.D. and T-test, etc. The hypothesis has been tested statistically to arrive at 
conclusion and policy implication.  
5. Literature Review 
Financial statements analysis is mainly concerned with the understanding of company accounts and 
interpretation of the published financial statements to enable legitimate users to make informed economic 
decisions. Financial analysis is the process of identifying the financial strengths and weaknesses of the firm 
by properly establishing relationship between the items of the balance sheet and the profit and loss account 
(Pandey, 1991). Analysis of financial statements is of interest to lenders, security analysts, managers and 
others (Prasanna, 1995). Trade creditors are interested in the firm’s ability to meet their claims. Their analysis 
will therefore, confine to the evaluation of the firm’s liquidity position. The suppliers are concerned with the 
firm’s solvency and survival. They analyze the firm’s profitability over time. Long term creditors place more 
emphasis on the firm’s solvency and profitability. The investors are most concerned about the firm’s earnings. 
So, they concentrate on the analysis of the firm’s present and future profitability as well as earning ability and 
risk (Abu Sina, 1998). Financial ratios are the simplest tools for evaluating the financial performance of the 
firm (Chin-Feng, 2005). One can employ financial ratios to determine a firm’s liquidity, profitability, 
solvency, capital structure and asset turnover. Hannan (1998) used financial ratios to show the financial 
position and performance analysis of Bangladesh Shilpa Bank. He showed that techniques of financial 
analysis can be used in the evaluation of financial position and performance of financial institution as well as 
non financial institutions even Development Financial Institutions (DFI). Altman (1968) used financial ratios 
to predict corporate bankruptcy. He found that the bankruptcy model has an accuracy rate of 93% and is very 
successful in predicting failed and non-failed firms. Sina (1998) used financial ratios to test the financial 
strengths and weaknesses of Khulna Newsprint Mills Ltd. He found that due to lack of planning and control 
of working capital, operational inefficiency, obsolete store, ineffective credit policy, increased cost of raw 
materials, labor and overhead, the position of the company was not good. Jahur (1995) used financial ratios to 
measure operational performance of limited company. He used profitability, liquidity, activity and capital 
structure to measure operational performance. Jahur (1996) used Altman’s MDA model to conclude the 
bankruptcy position of Chittagong Steel Mills Ltd. He found that absences of realistic goals, strict govt. 
regulation are the main reasons for the lowest level of bankruptcy. Ohlson (1980) employed financial ratios to 
predict a firm’s crisis. He found that there are four factors affecting a firm’s vulnerability. These factors are 
the firm’s scale, financial structure, performance and liquidity. In the article “The Assessment of Financial 
and Operating Performance of the Cement Industry: A Case Study of Confidence Cement Limited”, Dipak & 
Milan (2001) found that the investment in cement was fairly profitable. Salauddin (2001) examined the 
profitability of the Pharmaceutical Companies of Bangladesh. By using ratio analysis, mean, standard 
deviation and co-efficient of variation he found that the profitability of the Pharmaceuticals sector was very 
satisfactory in terms of the standard norms of return on investment. Hye & Rahman (1997) conducted a 
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research to assess the performance of the selected private sector general insurance companies in Bangladesh. 
The study revealed that the private sector insurance companies had made substantial progress. The study 
found that the insurance companies were keeping their surplus funds in the form of fixed deposits with 
different commercial banks due to absence of suitable revenues for investment. Salim & Kabir (1996) 
examined the financial performance of Bangladesh Shipping Corporation. They found that conversion of 
long-term debt to equity may improve the financial performance of Bangladesh Shipping Corporation to a 
greater extent.  These studies show that the ratio analysis and MDA are the good method to evaluate firm 
performance. The researcher uses these tools to measure the financial performance of 9 selected 
Pharmaceutical firms in this paper. 
  
  
6. Theoretical discussion of Financial Ratio 
Financial analysis offers a system of appraisal and evaluation of a firm’s performance and operations; it is the 
analysis of the financial statement of an enterprise. The analysis of financial statement can be best done by 
various yardsticks of which, the important is known as ratio or percentage analysis. Ratio is a numerical or an 
arithmetical relation between two figures. It is expressed when one figure is divided by another. Accounting 
ratios show inter-relationship which exist among various accounting data. Accounting ratio can be expressed 
in various ways such as, a pure ratio, a rate or a percentage. Ratio analysis is certainly a very admirable device 
because it is simple and it has a predictive value. Management and other users thus, rely substantially on the 
financial ratios based on accounting data for making assessments and predictions of past performance, 
present position and probable future potentials. One important way for diagnosing the financial health is to 
measure the profitability, liquidity, activity and solvency and the level of the bankruptcy of enterprise. 
6.1 Profitability Ratio 
Profitability is a measure of efficiency. The profitability ratios measure the performance of profit of an 
enterprise. In other words the profitability ratios are designed to provide answers to questions such as what is 
the rate of profit?. What is EPS? What is the rate of investment? What is the rate of equity? Is the profit 
earned by the enterprise adequate? What is the dividend payout ratio? What is retention ratio and so on? The 
analysis of the profitability ratio is important for the shareholders, creditors, prospective investors, bankers 
and the government alike. Gross profit margin ratio, return on investment, net profit margin ratio and 
operating profit ratio can be used to measure the profitability position of the enterprise. 
6.2 Liquidity Ratio 
The liquidity ratios measure the ability of an enterprise to meet its short-term obligations and reflect the 
short-term financial strength of an enterprise. Liquidity is a pre-requisite for the very survival of an enterprise. 
Analysis of liquidity is very important in knowing the liquidity status, movement of funds, idle fund (if any) 
which will not only help financial management to keep the liquidity position of the company  in order but 
also make sure of payment to short-term creditors, interested in short-term solvency of the company. 
Liquidity ratios reveal the rate at which fixed and working assets are being converted into cash and the time 
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when the cash will be required. Current ratio, quick ratio and working capital to total asset ratio can be used to 
measure the liquidity position of the enterprise. 
6.3 Activity Ratio 
Activity ratios indicate the effectiveness of an enterprise with which different assets are managed and utilized 
in a business. The efficiency in assets management is measured by activity ratio which involves the 
comparisons between the level of sales and investment in various assets accounts, inventories, bills 
receivable, fixed assets and others. The activity can be measured by the use of activity ratios such as 
inventory turnover, fixed assets turnover and total assets turnover. 
6.4 Solvency Ratio 
The long-term solvency of a company is an important aspect to the present and future long-term creditors, 
banks, debenture holders etc. Before sanctioning loan or buying a debenture or preference share, they are 
interested to see whether the company has ability to pay the interest regularly as well as repay the installment 
of the principal on due date or in one lump sum at the time of maturity. The long-run solvency of a company 
can be measured by the use of solvency ratios named debt to total assets, the time interest earned and retained 
earning to total assets. 
7. Findings and Discussions 
7.1 Profitability Ratio 
The tables (01, 02,03,04,05 and 06) depict various financial ratios covering profitability of the selected 
Pharmaceuticals for the period under study. 
(Insert Table-01 here) 
  
 
7.1.1 Gross Profit Margin 
The earnings in terms of sales can be assessed through the profit margin. The gross profit margin reflects the 
effectiveness of pricing policy and of production efficiency. Some authors consider that a profit margin ratio 
ranging from 20% to 30% has been considered as the standard norm for any industrial enterprise. The 
table-01 shows that the average gross profit ratios range from highest 34.43% in BXPHARMA to lowest 
9.42% in BEACONPHAR. The study is also found that the industry average gross profit ratio was 17.69% 
and the average gross profit ratio of all but five samples was below industry average. In view of standard, the 
gross profit margin of SQURPHARMA, IBNSINA, BXPHARMA, and AMBEEPHA during the period was 
higher than standard norm and shown an increasing trend but the ratio for ACTIVEFINE, RENETA, 
BEACONPHAR, PHARMAID and BPL was lower than the standard. The higher ratio indicates favorable 
purchasing and markup policies and the ability of management to develop sales volume and lower ratio 
indicates unfavorable purchasing and markup policies and the inability of management to develop sales 
volume. This ratio also indicates that the selected enterprise (SQURPHARMA, IBNSINA, BXPHARMA, 
and AMBEEPHA) seems to be in an advantage position to service in the face of falling sales prices, rising 
cost of production or decline demand for the product. From the calculated value of t it is seen that there is a 
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significant difference in gross profit ratio between industry average and individual pharmaceuticals firms 
except SQURPHARMA and AMBEEPHA. 
(Insert Table-02 here) 
  
7.1.2 Net Profit Margin 
The ratio reveals the overall profitability of the concern, that’s why it is very useful to the proprietors and 
prospective investors. It also indicates management efficiency in manufacturing, administrating and selling 
of the products. The table-02 shows that the net profit ratios range from highest 10.75% in SQURPHARMA 
to lowest 13.36 %( negative) in BXPHARMA. SQURPHARMA earned the highest average net profit margin 
(10.75%) and industry average is 1.35%. The calculated ratios in table-02 indicate that the average net profit 
ratio of ACTIVEFINE, SQURPHARMA, IBNSINA, RENETA, AMBEEPHA, and PHARMAID are higher 
than industry average. BXPHARMA, BEACONPHAR and BPL are below industry average. Calculated 
values of t’ state that there is a significant difference in net profit ratio between industry average and 5 
individual pharmaceuticals firms (SQURPHARMA, IBNSINA, BEACONPHAR, PHARMAID and BPL). 
For other pharmaceuticals the difference is insignificant. 
(Insert Table-03 here) 
  
7.1.3 Return on Investment (ROI) 
This ratio measures the profitability of enterprise on total investment. The Planning Commission, 
Government of Bangladesh has declared that the entire existing project in the public sector would have to 
guarantee a fixed return to 7.5% of the investment. This may be considered as the standard norm for the 
industrial enterprise. The table-03 shows that the return on investment on an average for the period under 
study varies from maximum 24.38% in SQURPHARMA to minimum 3.77% (negative) in BPL and the 
industry average is 6.67% which is lower than the standard norm of 7.5% . The ratio for BXPHARMA is 
negative. It is seen from the table that ACTIVEFINE, BXPHARMA, RENETA, BEACONPHAR, 
PHARMAID and BPL have a low ratio as compared to the industry average and standard norm, which is 
indicative of poor earning in terms of investment, the return on investment for SQURPHARMA(24.38%), 
IBNSINA (14.39%) and AMBEEPHA (11.16%) should be considered as extremely satisfactory as they are 
more than the industry average ratio and as well as the standard norm and this ratios are indicative of very 
good profitability in terms of investment. ACTIVEFINE, BXPHARMA, RENETA, BEACONPHAR, 
PHARMAID and BPL show a declining trend which indicates the inefficiency of the business as a whole. 
From the calculated value of t it is observed that there is a significant difference in return on investment 
between industry average and 5 individual pharmaceuticals firms (ACTIVEFINE, IBNSINA, BXPHARMA 
PHARMAID and BPL). For other pharmaceuticals the difference is insignificant. 
(Insert Table-04 here) 
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7.1.4 Operating Profit Ratio 
Operating Profit refers to the profit of an enterprise, which is obtained after deducting all operating expenses 
from gross profit. This ratio establishes the relationship between operating profit and sales. It represents the 
overall earnings of an enterprise and one can get a clear idea about the efficiency of an enterprise from its 
operating profit ratio. The higher the ratio, the better is the overall efficiency of the enterprise. Operating 
profit ratio ranging 4% to 6% is considered norm for the purpose of comparison and control by some authors 
(Jain and Narang, Jahur, Hye). The table-04 shows that the average operating profit ratio of the sample 
pharmaceuticals ranges from highest 29.02% in BXPHARMA to lowest 0.41% in BEACONPHAR. The 
industry average operating profit ratio is 10.70% and most of the companies (5 out of 9) failed to attain the 
average but most of the companies’(4 out of 9) operating profit ratio is more than standard. From the 
calculated value of t it is observed that there is a significant difference in operating profit ratio between 
industry average and almost all individual pharmaceuticals firms except SQURPHARMA. 
(Insert Table-05 here) 
  
7.1.5 Return on Capital Employed 
The most independent ratio for assessment of profitability is the return on capital employed. It reflects the 
overall efficiency with which capital is used. Here, Capital Employed=Equity share capital + Preference 
share capital+ Undistributed profit+ Reserve and Surplus+ Long term Liabilities- Fictitious Assets. A rate of 
return ranging from 11% to 12% on Capital employed may be considered as reasonable for a selected 
enterprise. The table-05 represents the return on capital employed ratio of the sample pharmaceuticals for the 
study period. The table shows that the average returns on capital employed ranges from 1.46% in BPL to 
13.79% in SQURPHARMA and the average ratio is negative for BXPHARMA (-7.52%).  It appears from 
the table that the industry average return on capital employed is 3.59% which is not satisfactory in terms of 
the standard norm. It is seen from the table that SQURPHARMA has a high ratio as compared with standard 
norm, IBNSINA, AMBEEPHA and PHARMAID have a high ratio as compared to industry average. 
ACTIVEFINE, BXPHARMA, RENETA, BEACONPHAR and BPL have a lower ratio than industry 
average, which is indicative of poor earning in terms of capital employed. From the calculated value of t it is 
observed that there is a significant difference in return on capital employed between industry average and 4 
individual pharmaceuticals firms (ACTIVEFINE, SQURPHARMA, and BPL). For other pharmaceuticals 
the difference is insignificant. 
(Insert Table-06 here) 
  
7.1.6 Return on Total Assets 
This ratio is calculated to measure the profit after the tax against the amount invested in total assets to 
ascertain whether assets are being utilized properly or not. Some authors consider 10% to 12% rate of return 
on total assets as reasonable norm for a profitable firms and this may be considered as reasonable norm for the 
selected enterprises. Table -06 shows that the average return on total assets ranges from 3.77% (negative) in 
BXPHARMA to 7.42% in SQURPHARMA and the average return on total assets for BXPHARMA is 
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negative. It is seen from the table that the average return on total assets is 1.82% which is far away from 
standard norm. The average returns on total assets of all pharmaceuticals are below the standard norm which 
cannot be considered as satisfactory and desirable. The average return on total assets of BEACONPHAR 
(0.70%), BXPHARMA (-3.77%), AMBEEPHA (1.28%) and BPL (0.59%) are below the industry average. 
The calculated ratios show a decreasing trend for most of the pharmaceuticals during the period of study and 
lower ratios indicate the assets were not being utilized properly during the period. The calculated values of t 
state that there is a significant difference in return on total assets between industry average and 4 individual 
pharmaceuticals firms (SQURPHARMA, BEACONPHAR, PHARMAID and BPL). For other 
pharmaceuticals the difference is insignificant. 
7.2 Liquidity Ratio 
The Current Ratio and Quick Ratio, Current Assets to Fixed Assets and Net Working Capital to Total Assets 
are used to assess liquidity position of an enterprise. The tables (07, 08, 09, and10) depict various financial 
ratios covering liquidity of the selected pharmaceuticals for the period under study. 
(Insert Table-07 here) 
  
  
7.2.1 Current Ratio 
This ratio is a measure of the firm’s short term solvency of the firm’s liquidity. It indicates the ability of the 
company to meet its current obligations. If the current ratio is too low, the firm may have difficulty in meeting 
short run commitment. If the ratio is too high the firm may have an excessive investment in current assets or 
be under utilizing short term credit. Some authors consider 2:1 as standard norm for current ratio. Table-07 
shows that the industry average current ratio is 0.94:1 which indicates that the industry is not able to meet its 
current obligations from its current assets. The average current ratio ranges from 0.57:1 in AMBEEPHA to 
1.12:1 in SQURPHARMA. The average current ratios of BEACONPHAR (0.61:1), AMBEEPHA (0.57:1) 
and BPL (0.85:1) are below the industry average as well as below the standard norm. The average current 
ratios of ACTIVEFINE (1.08:1), SQURPHARMA (1.12:1), IBNSINA (1.10:1), BXPHARMA (1.06:1), 
RENETA (1.08:1) and PHARMAID (0.98:1) are above the industry average but below the standard norm. It 
is seen from the table that all these ratios are far from standard norm. Therefore it can be said that the liquidity 
in terms of current ratio had been quite inadequate in all the years under study for all the pharmaceuticals. The 
downward trend of current ratios of BXPHARMA, RENETA, BEACONPHAR, AMBEEPHA, PHARMAID 
and BPL indicate the inefficient liquidity management in case of the selected pharmaceuticals, the financial 
position is very unsatisfactory and the companies’ short term solvency is threatened. From the calculated 
value of t it is seen that there is a significant difference in current ratio between industry average and 4 
individual pharmaceuticals firms (RENETA, BEACONPHAR, AMBEEPHA, and PHARMAID). For other 
pharmaceuticals the difference is insignificant. 
(Insert Table-08 here) 
  
7.2.2 Liquid (Quick or Acid Test) Ratio 
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It measures the firm’s ability to meet short term obligations from its most liquid assets. Table-08 shows that 
the industry average of liquid ratio is 0.57:1 which is very lower than the standard (1:1) ratio. The table 
reveals that the average liquid ratio ranges from 0.29:1 in IBNSINA and in BEACONPHAR to 1.28:1 in 
ACTIVEFINE. The average liquid ratios of IBNSINA (0.29:1), RENETA (0.55:1), BEACONPHAR 
(0.29:1), AMBEEPHA (0.38:1) and BPL (0.43:1) are below the industry average as well as far away from 
standard norm and the average ratios of SQURPHARMA (0.64:1), BXPHARMA (0.59:1), and PHARMAID 
(0.70:1) are above the industry average but below the standard norm. It indicates that all pharmaceuticals 
except ACTIVEFINE (average liquid ratio is 1.28:1) are financially very weak and have no ability to pay its 
most immediate liabilities. It is also observed that this position is declining for most of the pharmaceuticals 
and it is the dangerous signal for the companies. From the calculated value of t it is observed that there is a 
significant difference in liquid ratio between industry average and 4 individual pharmaceuticals firms 
(ACTIVEFINE, IBNSINA, BEACONPHAR and AMBEEPHA). For other pharmaceuticals the difference is 
insignificant. 
(Insert Table-09 here) 
  
7.2.3 Current Assets to Fixed Assets 
Another criterion for liquidity assessment is the ratio between current assets to fixed assets. This ratio will 
differ from industry to industry and, therefore, no standard can be laid down. The table-09 shows that the 
industry average current asset to fixed assets is 0.78:1. It is seen from the table that the average current assets 
to fixed assets ratio ranges from 0.40:1 in ACTIVEFINE to 1.06:1 in SQURPHARMA and the average ratio 
for ACTIVEFINE (0.40:1), RENETA (0.51:1) and BPL (0.61:1) is lower than industry average and the 
average ratio for SQURPHARMA (1.06:1), IBNSINA (0.79:01),BXPHARMA(0.94:1), BEACONPHAR 
(0.89:1), AMBEEPHA (0.92:1) and PHARMAID (0.93:1) is higher than the industry average. The calculated 
ratios show a decreasing trend for some pharmaceuticals which mean that trading is slack or more 
mechanization has been put through in that pharmaceuticals. From the calculated value of t it is observed that 
there is a significant difference in current assets to fixed assets between industry average and 01 individual 
pharmaceuticals firms (ACTIVEFINE). For all other pharmaceuticals the difference is insignificant. 
(Insert Table-10 here) 
  
  
  
  
7.2.4 Net Working Capital to Total Assets 
Table-10 shows net working capital to total assets ratios for the selected pharmaceuticals for the study period. 
It is seen from the table that the industry average of net working capital to total assets ratio is -0.01. The table 
reveals that the average net working capital to total assets ratios of ACTIVEFINE (0.04), SQURPHARMA 
(0.05), IBNSINA (0.02), BXPHARMA (0.01), RENETA (0.02) and BPL (0.04) are higher than industry 
average and the average ratio of BEACONPHAR (-0.30), AMBEEPHA (-0.0004), PHARMAID (-0.01), are 
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lower than or equal industry average. From the calculated ratios it is clearly seen that the net working capital 
to total assets ratios are very small and for three pharmaceuticals the ratio is negative. Such state of affairs 
indicates the inability and inadequacy of net working capital to cover the total assets of the selected enterprise 
for the period under review. From the value of t it is observed that there is a significant difference in net 
working capital to total assets between industry average and 4 individual pharmaceuticals firms (RENETA, 
BEACONPHAR, AMBEEPHA and PHARMAID). For other pharmaceuticals the difference is insignificant. 
7.3 Activity Ratios 
Activity ratios show the intensity with which the firm uses its assets in generation sales. These ratios indicate 
whether the firm’s investments in current and long-term assets are too small or too large. The objective is to 
have “enough” assets but not “too many”. The tables (11, 12, and13) depict various activity ratios of the 
selected pharmaceuticals for the period under study. 
(Insert Table-11 here) 
  
7.3.1 Inventory Turnover Ratio 
This ratio is also known as stock turnover ratio, establishes relationship between sales (or cost of goods sold) 
and the total inventory (or average inventory). A low inventory turnover may indicate an excessive 
investment in inventories a high ratio often means that the firm is running out of stock, resulting in poor 
service to customers. It assists the financial manager in evaluating inventory policy to avoid any danger of 
over stocking as a prelude to the effective utilization of the resources of the firm. Higher the ratio the better it 
is because it shows that stock is rapidly turned over. The table-11 shows that the industry average inventory 
turnover is 6.45 times. It is seen from the table that the average inventory turnover ratio ranges from 1.47 
times in BXPHARMA to 19.99 times in ACTIVEFINE. Some authors consider 8 to 9 times of inventory 
turnover ratio as the reasonable norm for an efficient concern. From the study it is seen that the average 
inventory turnover for all selected  pharmaceuticals except three pharmaceuticals, ACTIVEFINE(19.99 
times), BEACONPHAR (9.52), PHARMAID (8.13), is lower than the industry average as well as standard 
norm which implies excessive inventory levels or a slow moving or obsolete inventories. If it is the obsolete 
inventories then it has to be written off. This will adversely affect the working capital and liquidity position of 
the firm. The calculated ratios indicate that the sale management of the selected pharmaceuticals can’t be said 
to be efficient to sell its product. The values of t state that there is a significant difference in inventory 
turnover between industry average and 4 individual pharmaceuticals firms (ACTIVEFINE, SQURPHARMA, 
IBNSINA and BXPHARMA). For other pharmaceuticals the difference is insignificant. 
 (Insert Table-12 here) 
                                                                                                                                                                            
                                                                                                                                                                            
 7.3.2 Net Fixed Assets Turnover 
The ratio indicates the extent of generating sales volume in terms of net fixed assets. Some authors consider 
that an ideal fixed assets turnover for an enterprise should be 5 times of net fixed assets and hence this may 
also be considered so far over selected case. Table-12 shows the net fixed assets turnover ratios for the 
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selected pharmaceuticals for the study period. From the calculated ratios it is seen that the industry average 
net fixed assets turnover is 1.89 which is far away from the standard. The average ratio ranges from 0.58 
times in BXPHARMA to 4.41 times in BPL. The average ratio of ACTIVEFINE (1.17times), 
SQURPHARMA (1.41times), IBNSINA (1.16 times), BXPHARMA (0.58 times), RENETA (0.94 times) 
and AMBEEPHA (1.45 times) is lower than industry average as well as very lower than standard. Only three 
pharmaceuticals, BEACONPHAR (3.87 times), PHARMAID (2.02 times), BPL (4.41 times), have average 
ratio more than industry average but lower than standard. This low level of ratio indicates poor sales volume 
in terms of fixed assets. This indicates an inefficient use of fixed capital. From the calculated value of t it is 
observed that there is a significant difference in net fixed assets turnover between industry average and 7 
individual pharmaceuticals firms (ACTIVEFINE, IBNSINA, BXPHARMA, RENETA, BEACONPHAR, 
AMBEEPHA, and BPL). For other pharmaceuticals the difference is insignificant. 
(Insert Table-13 here) 
  
7.3.3 Total Assets Turnover 
Another activity ratio is total assets turnover. This is a measure of the extent of generating sales in terms of 
the total assets. A standard norm of 200% (i.e. 2 times) of this ratio is considered norm by some authors for an 
industrial enterprise. This may also be taken as such for our selected pharmaceuticals. Table-13 reveals that 
the average total assets turnover ratio ranges from 0.30 times in BXPHARMA to 2.04 times in 
BEACONPHAR and the industry average is 0.90 times which is very lower than standard norm. It is seen 
from the table that the average ratio of ACTIVEFINE (0.81 times), SQURPHARMA (0.69 times), IBNSINA 
(0.65 times), BXPHARMA (0.30 times), RENETA (0.62 times) and AMBEEPHA (0.77 times) is lower than 
the industry average as well as standard norm, but the average ratio of BEACONPHAR (2.04 times), 
PHARMAID (1.00 time), BPL (1.24 times)  is higher than industry average as well as standard norm. From 
the calculated value of t it is observed that there is a significant difference in total assets turnover between 
industry average and 6 individual pharmaceuticals firms (SQURPHARMA, IBNSINA, BXPHARMA, 
RENETA, AMBEEPHA and BEACONPHAR). For other pharmaceuticals the difference is insignificant. 
  
7.4 Solvency Ratios 
Debt-Equity ratio and Debt to Total Assets ratio are commonly used solvency ratios. The tables (14 and 15) 
depict various solvency ratios of the selected pharmaceuticals for the period under study. 
(Insert Table-14 here) 
  
7.4.1 Debt-Equity Ratio 
Equity represents a “cushion” for share-holders. This is a ratio calculated to measure the relative proportions 
of outsiders’ funds and shareholder’ funds invested in the company. This ratio is also known as 
external-internal equity ratio. The standard ratio is 2:1. The table-14 shows the debt-equity ratio for the 
selected pharmaceuticals for the study period. It is revealed from the table that the average debt-equity ratio is 
2.12:1. The debt-equity ratio ranges from 0.33:1 in ACTIVEFINE to 7.23:1 in AMBEEPHA. It is seen from 
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the table that the average ratio of ACTIVEFINE (0.33:1), SQURPHARMA (1.08:1), IBNSINA (0.65:1), 
RENETA (1.24:1) and BPL (0.65:1) is lower than the industry average as well as standard norm, but the 
average ratio of BXPHARMA (2.27:1), BEACONPHAR (3.19:1), AMBEEPHA (7.23:1) and PHARMAID 
(2.44:1) is higher than the industry average as well as standard norm. These low levels of debt-equity ratio of 
ACTIVEFINE, SQURPHARMA, IBNSINA, RENETA and BPL mean that the claims of creditors are lower 
than those of owners and the company has not liberally used debt to finance its assets. It indicates an 
inefficient financial management. On the other hand the position is strong for BXPHARMA, 
BEACONPHAR, AMBEEPHA and PHARMAID. From the calculated value of t it is seen that there is a 
significant difference in debt-equity ratio between industry average and 7 individual pharmaceuticals firms 
except BXPHARMA and BEACONPHAR. 
(Insert Table-15 here) 
  
7.4.2 Debt to Total Assets Ratio 
The objective of this ratio is to assign what portion of total assets (debt + equity) is collected from debt. Some 
authors consider that debt to total assets ratio should be 50% for an industrial enterprise. The table-15 shows 
the debt to total assets ratio for the selected pharmaceuticals for the study period. It is observed from the table 
that the industry average debt equity ratio is 36% which is lower than the standard norm. It is also seen from 
the table that the average ratio ranges from 7% in ACTIVEFINE to 83% in AMBEEPHA. The calculated 
ratios indicate the claim of creditors is about to very small in percentage to the shareholders of ACTIVEFINE 
(7%), SQURPHARMA (28%), IBNSINA (35%), RENETA (33%), and BEACONPHAR (24%), 
PHARMAID (27% and BPL (13%) Such a lower ratio of debts to total assets of selected pharmaceuticals 
reveals the fact that they are less dependent on debt rather than on their own capital for financing their 
projects. On the other hand the average ratio of BXPHARMA (75%) and AMBEEPHA (83%) is higher than 
the average as well as the standard norm which indicates that BXPHARMA and AMBEEPHA are more 
dependent on debt rather than their own capital for financing project. From the calculated value of t it is 
observed that there is a significant difference in debt to total assets between industry average and 6 individual 
pharmaceuticals firms (ACTIVEFINE, BXPHARMA, BEACONPHAR, AMBEEPHA, PHARMAID and 
BPL). For other pharmaceuticals the difference is insignificant. 
  
8. Testing financial soundness of selected Pharmaceutical Companies: 
After examining profitability, liquidity, activity and solvency of selected Pharmaceutical Companies, now it 
is necessary to examine the overall financial soundness of these companies during the study period. In this 
context Multivariate Discriminate Analysis (MDA) model as developed by Prof. Altman may be considered 
worth while. The said model can give some rough idea about the financial soundness of the selected 
Pharmaceuticals. He developed the following equation for judging the financial soundness of an enterprise: 
Z = 0.012T1 + 0.014T2 + 0.033T3 + 0.006T4 + 0.999T5 
Where; 
             T1: Working Capital / Total Assets 
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             T2: Retained earnings / Total Assets 
             T3: Earning before interest & taxes / Total Assets 
             T4: Market value of equity / Total debt 
             T5: Sales / Total Assets 
             Z: Overall index 
In order to test the overall financial soundness of the selected pharmaceuticals, it needs to calculate the ratios 
of working capital to total assets, retained earnings to total assets, earning before interest & taxes to total 
assets, market value of equity to book value of total debt and sales to total assets. 
(Insert Table-16 here) 
  
The table-16 depicts the year wise as well as average position of the ratios of working capital to total assets, 
retained earnings to total assets, earning before interest and taxes to total assets, market value of equity to 
total debt and sales to total assets. 
  
 (Insert Table-17 here) 
  
The Table-17 shows the year-wise as well as average position of Z’s score of the sample pharmaceuticals 
during the study period. After putting the respective average values of T1, T2, T3, T4 and T5, in the aforesaid 
equations as developed by Prof. Altman, Z score was estimated. The average Z score ranges from 0.30 in 
BXPHARMA to 2.03 in BEACONPHAR and the industry average Z score is 0.91 comparing with Prof. 
Altman’s conclusion that firms with Z score above 2.99 were solvent while those below Z score of 1.81 were 
bankrupt. Average Z score of sample pharmaceutical ACTIVEFINE (0.83), SQURPHARMA (0.73), 
IBNSINA (0.65), BXPHARMA (0.30), RENETA (0.63), AMBEEPHA (0.75) are lower than the industry 
average as well as the range provided by Prof. Altman. On the other hand average Z score of sample 
pharmaceuticals of PHARMAID (1.00) and BPL (1.24) are higher than the industry average but lower than 
the range provided by Prof. Altman. Only Z score of BEACONPHAR (2.03) exists within the range provided 
by Prof. Altman. The table shows the position of bankruptcy at a lower level during the period for all the 
selected pharmaceuticals except BEACONPHAR. 
It can be concluded that the overall financial soundness of the sample Industry during the study period had 
been worst leading to total bankruptcy of the industry. From the calculated value of t it is observed that there 
is a significant difference in Z score between industry average and 6 individual pharmaceuticals firms 
(SQURPHARMA, IBNSINA, BXPHARMA, RENETA, BEACONPHAR and AMBEEPHA). For other 
pharmaceuticals the difference is insignificant. 
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9. Conclusions 
From the discussion it can be concluded that the financial position and operational performance of the most of 
the selected pharmaceuticals were not satisfactory. The inefficiency of financial management may be a major 
cause for such a poor position of the state of affairs. By applying Prof. Altman’s MDA model it is seen that 
the overall financial position of the sample pharmaceuticals was at the lower level of bankruptcy except only 
one pharmaceuticals (BEACONPHAR). The main reasons attributed to such a situation were reported to be 
poor market demands, scarcity of raw materials, high competition, vanished quota system, management in 
attention, lack of realistic goals, strict government regulations, political instability, increased price of raw 
materials and others adverse environmental factors etc. In order to save the pharmaceuticals from total 
bankruptcy the financial performance of the sample pharmaceuticals should be improved as early as possible. 
The followings are the recommendations: 
       i.   The financial management specially purchase, sales and inventory management have to be motivated, 
so that they act all the tasks cordially, efficiently and honestly. 
      ii.   The Pharmaceuticals should regularly make use of ratio analysis and measure should be taken to 
improve undesirable ratios at least as to the point of industry’s average. 
    iii.   Qualified, trained and experienced management personnel should be appointed. 
     iv.   Government regulations should be flexible and policy should be realistic. 
       v.   Operational efficiency should be increased by reducing cost and wastage and improving operating and 
management performance. Supply of working capital should be adequate. 
     vi.   Liquidity position of the selected Pharmaceuticals should be improved by reducing current liabilities. 
   vii.   A reasonable credit policy should be implemented, so that the main portion of profit does not spend in 
payment of fixed charges. 
  viii.   Accountability and motivation for achievement of performance should be fixed up. 
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Table-01: Gross Profit Margin 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result 
(Ho) 
ACTIVEFINE 11 13.56 13.51 12.69 17.69 1.46 5.95 4.30 Rejected 
SQURPHARMA 22.13 22.84 16.87 20.61 17.69 3.26 1.55 4.30 Accepted 
IBNSINA 21.98 21.46 19.89 21.11 17.69 1.09 5.43 4.30 Rejected 
BXPHARMA 39.03 29.18 35.08 34.43 17.69 4.96 5.83 4.30 Rejected 
RENETA 9.62 10.12 11.82 10.52 17.69 1.15 10.86 4.30 Rejected 
BEACONPHAR 9.70 9.28 9.27 9.42 17.69 0.25 59.07 4.30 Rejected 
AMBEEPHA 18.44 19.90 22.57 20.30 17.69 2.09 2.16 4.30 Accepted 
PHARMAID 14.16 14.25 14.32 14.24 17.69 0.08 69.00 4.30 Rejected 
BPL 16.22 16.23 15 15.82 17.69 0.71 4.56 4.30 Rejected 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). 
  
Table-02: Net Profit Margin 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result 
(Ho) 
ACTIVEFINE 1.80 2.40 2.53 2.24 1.35 0.39  3.87 4.30 Accepted 
SQURPHARMA 13.31 11.13 7.83 10.75 1.35 2.76 5.88 4.30 Rejected 
IBNSINA 3.87 4.67 4.78 4.44 1.35 0.50 10.66 4.30 Rejected 
BXPHARMA (4.01) (23.30) (12.79) (13.36) 1.35 9.66 2.64 4.30 Accepted 
RENETA 2.71 3.35 4.50 3.52 1.35 0.91 4.09 4.30 Accepted 
BEACONPHAR 0.52 0.22 0.30 0.34 1.35 0.16 11.22 4.30 Rejected 
AMBEEPHA 0.97 0.96 2.28 1.40 1.35 0.76 0.11 4.30 Accepted 
PHARMAID 2.34 2.50 2.26 2.37 1.35 0.12 14.57 4.30 Rejected 
BPL 0.72 0.52 0.20 0.48 1.35 0.26 5.80 4.30 Rejected 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). 
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Table-03: Return on Investment 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result (Ho) 
ACTIVEFINE 2.57 2.93 3.09 2.86 6.67 0.27 23.81 4.30 Rejected 
SQURPHARMA 20.72 32.93 19.48 24.38 6.67 7.43 4.13 4.30 Accepted 
IBNSINA 11.79 15.73 15.64 14.39 6.67 2.25 5.94 4.30 Rejected 
BXPHARMA (1.39) (6.74) (3.19) -3.77 6.67 2.72 6.65 4.30 Rejected 
RENETA 3.69 4.79 6.20 4.89 6.67 1.26 2.44 4.30 Accepted 
BEACONPHAR 4.77 2.01 2.21 3.00 6.67 1.54 4.13 4.30 Accepted 
AMBEEPHA 6.85 8.90 17.72 11.16 6.67 5.78 1.34 4.30 Accepted 
PHARMAID 2.27 2.35 2.45 2.36 6.67 0.09 86.2 4.30 Rejected 
BPL 0.75 0.76 0.70 0.74 6.67 0.03 296.5 4.30 Rejected 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). 
  
  
  
Table-04: Operating Profit Ratio 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result (Ho) 
ACTIVEFINE 3.92 5.27 5.32 4.84 10.70 0.79 12.74 4.30 Rejected 
SQURPHARMA 19.63 20.89 14.78 18.43 10.70 3.23 4.13 4.30 Accepted 
IBNSINA 18.09 16.47 15.18 16.58 10.70 1.46 7.00 4.30 Rejected 
BXPHARMA 29.61 23.34 34.11 29.02 10.70 5.41 5.85 4.30 Rejected 
RENETA 2.99 4.02 5.55 4.19 10.70 1.29 8.68 4.30 Rejected 
BEACONPHAR 0.61 0.26 0.35 0.41 10.70 0.18 102.9 4.30 Rejected 
AMBEEPHA 14.10 16.01 17.87 15.99 10.70 1.89 4.85 4.30 Rejected 
PHARMAID 2.85 3.05 2.35 2.75 10.70 0.36 37.86 4.30 Rejected 
BPL 4.23 3.35 4.78 4.12 10.70 0.72 15.67 4.30 Rejected 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). 
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Table-05: Return on Capital Employed 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result (Ho) 
ACTIVEFINE 2.03 2.32 2.45 2.27 3.59 0.21 11.00 4.30 Rejected 
SQURPHARMA 15.02 15.69 10.65 13.79 3.59 2.74 6.46 4.30 Rejected 
IBNSINA 3.70 5.01 5.60 4.77 3.59 0.97 2.11 4.30 Accepted 
BXPHARMA (2.32) (14.9) (5.35) (7.52) 3.59 6.57 2.92 4.30 Accepted 
RENETA 0.35 3.09 4.31 2.58 3.59 2.03 0.86 4.30 Accepted 
BEACONPHAR 4.77 2.01 2.21 3.00 3.59 1.54 0.66 4.30 Accepted 
AMBEEPHA 4.06 4.92 13.62 7.53 3.59 5.29 1.29 4.30 Accepted 
PHARMAID 3.70 4.33 5.21 4.41 3.59 0.76 1.86 4.30 Accepted 
BPL 1.53 1.59 1.25 1.46 3.59 0.18 21.3 4.30 Rejected 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). 
  
  
  
Table-06: Return on Total Assets 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result (Ho) 
ACTIVEFINE 1.61 1.88 2.01 1.83 1.82 0.20 .08 4.30 Accepted 
SQURPHARMA 9.00 8.27 5.00 7.42 1.82 2.13 4.55 4.30 Rejected 
IBNSINA 2.31 3.11 3.20 2.87 1.82 0.49 3.75 4.30 Accepted 
BXPHARMA (1.39) (6.74) (3.19) (3.77) 1.82 2.72 3.56 4.30 Accepted 
RENETA 2.23 3.09 4.31 3.21 1.82 1.05 2.28 4.30 Accepted 
BEACONPHAR 1.04 0.46 0.61 0.70 1.82 0.30 6.59 4.30 Rejected 
AMBEEPHA 0.82 1.02 2.00 1.28 1.82 0.63 1.5 4.30 Accepted 
PHARMAID 2.12 2.26 2.45 2.28 1.82 0.17 4.6 4.30 Rejected 
BPL 0.75 0.76 0.25 0.59 1.82 0.29 7.24 4.30 Rejected 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). 
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Table-07: Current Ratio 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result 
(Ho) 
ACTIVEFINE 1.26:1 1.51:1 1.74:1 1.08:1 0.94:1 0.24 1.00 4.30 Accepted 
SQURPHARMA 1.05:1 1.09:1 1.21:1 1.12:1 0.94:1 0.08 3.60 4.30 Accepted 
IBNSINA 0.98:1 1.13:1 1.19:1 1.10:1 0.94:1 0.11 2.67 4.30 Accepted 
BXPHARMA 1.27:1 0.98:1 0.92:1 1.06:1 0.94:1 0.19 1.09 4.30 Accepted 
RENETA 1.09:1 1.08:1 1.06:1 1.08:1 0.94:1 0.02 14.00 4.30 Rejected 
BEACONPHAR 0.70:1 0.60:1 0.52:1 0.61:1 0.94:1 0.09 6.60 4.30 Rejected 
AMBEEPHA 0.58:1 0.56:1 0.56:1 0.57:1 0.94:1 0.01 61.67 4.30 Rejected 
PHARMAID 0.98:1 0.97:1 0.98:1 0.98:1 0.94:1 0.01 6.67 4.30 Rejected 
BPL 0.98:1 0.90:1 0.67:1 0.85:1 0.94:1 0.16 1.00 4.30 Accepted 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). 
  
  
  
  
Table-08: Liquid/ Quick/ Acid Test Ratio 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result (Ho) 
ACTIVEFINE 1.06:1 1.31:1 1.47:1 1.28:1 0.57:1 0.21 464.33 4.30 Rejected 
SQURPHARMA 0.58:1 0.66:1 0.69:1 0.64:1 0.57:1 0.06 2.33 4.30 Accepted 
IBNSINA 0.35:1 0.34:1 0.18:1 0.29:1 0.57:1 0.10 4.67 4.30 Rejected 
BXPHARMA 0.68:1 0.52:1 0.57:1 0.59:1 0.57:1 0.08 0.40 4.30 Accepted 
RENETA 0.51:1 0.66:1 0.49:1 0.55:1 0.57:1 0.09 0.40 4.30 Accepted 
BEACONPHAR 0.32:1 0.23:1 0.33:1 0.29:1 0.57:1 0.06 9.33 4.30 Rejected 
AMBEEPHA 0.42:1 0.37:1 0.34:1 0.38:1 0.57:1 0.04 9.50 4.30 Rejected 
PHARMAID 0.59:1 0.76:1 0.74:1 0.70:1 0.57:1 0.09 2.60 4.30 Accepted 
BPL 0.47:1 0.50:1 0.32:1 0.43:1 0.57:1 0.10 2.33 4.30 Accepted 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). 
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Table-09: Current Assets to Fixed Assets 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result (Ho) 
ACTIVEFINE 0.35:1 0.40:1 0.46:1 0.40:1 0.78:1 0.06 12.67 4.30 Rejected 
SQURPHARMA 0.66:1 0.96:1 1.56:1 1.06:1 0.78:1 0.46 1.04 4.30 Accepted 
IBNSINA 0.58:1 0.74:1 1.04:1 0.79:1 0.78:1 0.23 0.08 4.30 Accepted 
BXPHARMA 1.04:1 1.16:1 0.61:1 0.94:1 0.78:1 0.29 0.94 4.30 Accepted 
RENETA 0.44:1 0.43:1 0.66:1 0.51:1 0.78:1 0.13 3.38 4.30 Accepted 
BEACONPHAR 1.22:1 0.85:1 0.60:1 0.89:1 0.78:1 0.31 0.61 4.30 Accepted 
AMBEEPHA 0.82:1 0.90:1 1.03:1 0.92:1 0.78:1 0.11 2.33 4.30 Accepted 
PHARMAID 0.79:1 0.90:1 1.09:1 0.93:1 0.78:1 0.15 1.67 4.30 Accepted 
BPL 0.50:1 0.74:1 0.60:1 0.61:1 0.78:1 0.12 2.43 4.30 Accepted 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). 
  
Table-10: Net Working Capital to Total Assets 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result 
(Ho) 
ACTIVEFINE (0.01) 0.04 0.08 0.04 (0.01) 0.04 2.50 4.30 Accepted 
SQURPHARMA 0.02 0.04 0.10 0.05 (0.01) 0.04 3.00 4.30 Accepted 
IBNSINA (0.01) 0.05 0.01 0.02 (0.01) 0.04 1.50 4.30 Accepted 
BXPHARMA 0.02 (0.01) (0.04) 0.01 (0.01) 0.03 1.00 4.30 Accepted 
RENETA 0.03 0.02 0.02 0.02 (0.01) 0.001 30.00 4.30 Rejected 
BEACONPHAR (0.23) (0.31) (0.35) (0.30) (0.01) 0.06 10.33 4.30 Rejected 
AMBEEPHA (0.0003) (0.0004) (0.0004) (0.0004) (0.01) 0.0001 104.00 4.30 Rejected 
PHARMAID (0.01) (0.01) (0.01) (0.01) (0.01) 0.003 10.00 4.30 Rejected 
BPL (0.01) (0.05) 0.18 0.04 (0.01) 0.12 0.71 4.30 Accepted 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). 
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Table-11: Inventory Turnover 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result (Ho) 
ACTIVEFINE 22.30 21.00 16.67 19.99 6.45 2.95 19.07 4.30 Rejected 
SQURPHARMA 4.09 4.26 2.76 3.70 6.45 0.82 5.85 4.30 Rejected 
IBNSINA 1.66 2.09 1.56 1.77 6.45 0.28 29.25 4.30 Rejected 
BXPHARMA 1.52 1.16 1.74 1.47 6.45 0.29 29.29 4.30 Rejected 
RENETA 3.64 5.64 2.79 4.03 6.45 1.46 2.88 4.30 Accepted 
BEACONPHAR 6.75 7.45 14.36 9.52 6.45 4.21 1.08 4.30 Accepted 
AMBEEPHA 3.82 5.70 4.14 4.55 6.45 1.01 3.28 4.30 Accepted 
PHARMAID 5.44 8.81 10.15 8.13 6.45 2.43 1.20 4.30 Accepted 
BPL 3.35 5.67 5.55 4.86 6.45 1.31 2.09 4.30 Accepted 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). 
  
Table-12: Net Fixed Assets Turnover 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result (Ho) 
ACTIVEFINE 1.22 1.12 1.17 1.17 1.89 0.05 24.00 4.30 Rejected 
SQURPHARMA 1.13 1.45 1.64 1.41 1.89 0.26 3.20 4.30 Accepted 
IBNSINA 0.95 1.16 1.36 1.16 1.89 0.21 6.08 4.30 Rejected 
BXPHARMA 0.71 0.63 0.40 0.58 1.89 0.16 14.56 4.30 Rejected 
RENETA 0.86 0.96 1.00 0.94 1.89 0.07 23.75 4.30 Rejected 
BEACONPHAR 4.43 3.96 3.23 3.87 1.89 0.60 5.66 4.30 Rejected 
AMBEEPHA 1.29 1.56 1.51 1.45 1.89 0.14 5.50 4.30 Rejected 
PHARMAID 1.72 1.71 2.63 2.02 1.89 0.53 0.42 4.30 Accepted 
BPL 2.34 2.87 2.03 4.41 1.89 0.42 10.50 4.30 Rejected 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). 
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Table-13: Total Assets Turnover 
Name of 
the  Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result 
(Ho) 
ACTIVEFINE 0.89 0.76 0.79 0.81 0.90 0.07 2.25 4.30 Accepted 
SQURPHARMA 0.68 0.74 0.64 0.69 0.90 0.05 7.00 4.30 Rejected 
IBNSINA 0.60 0.67 0.67 0.65 0.90 0.04 12.50 4.30 Rejected 
BXPHARMA 0.35 0.29 0.25 0.30 0.90 0.05 20.00 4.30 Rejected 
RENETA 0.59 0.67 0.60 0.62 0.90 0.04 14.00 4.30 Rejected 
BEACONPHAR 1.99 2.13 2.00 2.04 0.90 0.08 22.80 4.30 Rejected 
AMBEEPHA 0.72 0.84 0.74 0.77 0.90 0.06 4.33 4.30 Rejected 
PHARMAID 0.90 0.87 1.23 1.00 0.90 0.20 0.83 4.30 Accepted 
BPL 1.04 1.40 1.27 1.24 0.90 0.18 3.40 4.30 Accepted 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). 
  
Table-14: Debt-Equity Ratio 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result (Ho) 
ACTIVEFINE 0.35 0.32 0.31 0.33:1 2.12:1 0.02 179.00 4.30 Rejected 
SQURPHARMA 1.14 1.18 0.92 1.08:1 2.12:1 0.14 13.00 4.30 Rejected 
IBNSINA 0.60 0.61 0.75 0.65:1 2.12:1 0.08 29.40 4.30 Rejected 
BXPHARMA 2.03 2.45 2.33 2.27:1 2.12:1 0.22 1.15 4.30 Accepted 
RENETA 1.29 1.14 1.29 1.24:1 2.12:1 0.09 17.60 4.30 Rejected 
BEACONPHAR 3.59 3.33 2.64 3.19:1 2.12:1 0.49 3.82 4.30 Accepted 
AMBEEPHA 6.97 7.44 7.28 7.23:1 2.12:1 0.24 36.50 4.30 Rejected 
PHARMAID 2.21 2.48 2.71 2.44:1 2.12:1 0.25 2.29 4.30 Accepted 
BPL 0.39 0.58 0.98 0.65:1 2.12:1 0.30 8.65 4.30 Rejected 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). 
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Table-15: Debt to Total Assets Ratio 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result (Ho) 
ACTIVEFINE 0.08 0.07 0.06 0.07 0.36 0.01 48.33 4.30 Rejected 
SQURPHARMA 0.30 0.31 0.24 0.28 0.36 0.04 4.00 4.30 Accepted 
IBNSINA 0.35 0.36 0.34 0.35 0.36 0.01 1.67 4.30 Accepted 
BXPHARMA 0.74 0.76 0.74 0.75 0.36 0.01 65.00 4.30 Rejected 
RENETA 0.36 0.33 0.30 0.33 0.36 0.03 1.50 4.30 Accepted 
BEACONPHAR 0.20 0.25 0.27 0.24 0.36 0.04 6.00 4.30 Rejected 
AMBEEPHA 0.82 0.83 0.83 0.83 0.36 0.005 156.67 4.30 Rejected 
PHARMAID 0.30 0.27 0.24 0.27 0.36 0.03 4.50 4.30 Rejected 
BPL 0.13 0.17 0.10 0.13 0.36 0.04 11.50 4.30 Rejected 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). 
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Table: 16 (Ratios for Testing Financial Soundness) 
Ratios ACTIVEFINE SQURPHARMA IBNSINA BXPHARMA RENETA BEACONPHAR AMBEEPHA PHARMAID
Working 
Capital to 
Total 
Assets (in 
time) 
(0.005) 
0.040 
0.080 
0.038 
0.042 
  
0.019 
0.401 
0.104 
0.174 
0.200 
  
(0.007) 
0.047 
0.080 
0.04 
0.044 
  
0.108 
(0.012) 
(0.035) 
0.021 
0.077 
  
0.026 
0.024 
0.024 
0.025 
0.001 
  
(0.233) 
(0.307) 
(0.348) 
(0.296) 
0.0583 
  
(0.0003) 
(0.0004) 
(0.0004) 
(0.0004) 
0.00001 
  
Retained 
Earnings 
to Total 
Assets  (in 
time) 
0.007 
0.012 
0.017 
0.012 
0.005 
  
0.09 
0.083 
0.050 
0.074 
0.021 
  
0.016 
0.001 
0.003 
0.007 
0.008 
  
(0.014) 
(0.067) 
(0.032) 
(0.037) 
0.027 
  
(0.039) 
(0.036) 
(0.022) 
(0.032) 
0.009 
  
(0.314) 
(0.329) 
(0.390) 
(0.344) 
0.041 
  
0.0067 
0.0079 
0.0164 
0.0103 
0.0053 
  
Earning 
before 
interest 
and taxes 
to Total 
Assets (in 
time) 
0.019 
0.022 
0.024 
0.022 
0.003 
  
0.124 
0.129 
0.092 
0.115 
0.020 
  
0.078 
0.103 
0.095 
0.092 
0.013 
  
0.077 
0.024 
0.036 
0.045 
0.028 
  
0.37 
0.047 
0.051 
0.156 
0.185 
  
0.048 
0.050 
0.057 
0.052 
0.005 
  
0.099 
0.132 
0.137 
0.123 
0.021 
  
Market 
value of 
equity to 
Total 
Debt (in 
time) 
2.86 
3.125 
3.23 
3.072 
0.191 
  
0.88 
0.85 
1.09 
0.94 
0.131 
  
1.67 
1.64 
1.33 
1.547 
0.188 
  
0.49 
0.41 
0.43 
0.443 
0.042 
  
0.78 
0.88 
0.78 
0.813 
0.058 
  
0.28 
0.30 
0.38 
0.32 
0.053 
  
0.143 
0.134 
0.137 
0.138 
0.005 
  
Sales to 
Total 
Asset (in 
time) 
0.89 
0.76 
0.79 
0.813 
0.068 
  
0.68 
0.74 
0.64 
0.687 
0.050 
  
0.59 
0.68 
0.67 
0.647 
0.049 
  
0.35 
0.29 
0.25 
0.297 
0.050 
  
0.59 
0.67 
0.60 
0.62 
0.043 
  
1.99 
2.13 
2.00 
2.04 
0.078 
  
0.709 
0.819 
0.721 
0.749 
0.060 
  
  
Source: Annual Report and Official Records of the selected Pharmaceuticals industry, (2005-2008) 
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Table: 17 (Analysis of Z score) 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D t –value 
(Absolute 
value) 
Table 
value* 
Result 
(Ho) 
ACTIVEFINE 0.91 0.78 0.81 0.83 0.91 0.07 2.00 4.30 Accepted 
SQURPHARMA 0.69 0.75 0.76 0.73 0.91 0.04 9.00 4.30 Rejected 
IBNSINA 0.60 0.68 0.68 0.65 0.91 0.05 8.67 4.30 Rejected 
BXPHARMA 0.35 0.29 0.25 0.30 0.91 0.05 20.33 4.30 Rejected 
RENETA 0.61 0.68 0.61 0.63 0.91 0.04 14.00 4.30 Rejected 
BEACONPHAR 1.99 2.12 1.99 2.03 0.91 0.08 22.40 4.30 Rejected 
AMBEEPHA 0.71 0.82 0.73 0.75 0.91 0.06 5.33 4.30 Rejected 
PHARMAID 0.90 0.88 1.23 1.00 0.91 0.20 0.75 4.30 Accepted 
BPL 1.07 1.41 1.24 1.24 0.91 0.18 3.30 4.30 Accepted 
*Significant at the 0.05 level (2-tailed). 
  
  
  
List of Pharmaceuticals under study: 
  
Name of the Pharmaceuticals Short name used 
Active Fine Chemicals Limited ACTIVEFINE 
Square Pharmaceuticals Limited SQURPHARMA 
The Ibn Sina Pharmaceuticals ltd. IBNSINA 
Beximco Pharma BXPHARMA 
Renata Ltd. RENATA 
Beasel Pharmaceuticals Limited BEACONPHAR 
Ambee Pharma AMBEEPHA 
Pharma Aids PHARMAID 
Beacon Pharmaceuticals Limited BPL 
  
This academic article was published by The International Institute for Science, 
Technology and Education (IISTE).  The IISTE is a pioneer in the Open Access 
Publishing service based in the U.S. and Europe.  The aim of the institute is 
Accelerating Global Knowledge Sharing. 
 
More information about the publisher can be found in the IISTE’s homepage:  
http://www.iiste.org 
 
The IISTE is currently hosting more than 30 peer-reviewed academic journals and 
collaborating with academic institutions around the world.   Prospective authors of 
IISTE journals can find the submission instruction on the following page: 
http://www.iiste.org/Journals/ 
The IISTE editorial team promises to the review and publish all the qualified 
submissions in a fast manner. All the journals articles are available online to the 
readers all over the world without financial, legal, or technical barriers other than 
those inseparable from gaining access to the internet itself. Printed version of the 
journals is also available upon request of readers and authors.  
IISTE Knowledge Sharing Partners 
EBSCO, Index Copernicus, Ulrich's Periodicals Directory, JournalTOCS, PKP Open 
Archives Harvester, Bielefeld Academic Search Engine, Elektronische 
Zeitschriftenbibliothek EZB, Open J-Gate, OCLC WorldCat, Universe Digtial 
Library , NewJour, Google Scholar 
 
 
